Which stocks in any sector do Indian mutual fund managers prefer most? — April 2026 data
| # | Stock Name | No. of MFs Holding | Avg Weight (%) | Total MF Value (Cr) |
|---|---|---|---|---|
| 21 | Neuland Laboratories Limited | 102 funds | 0.96% | ₹2,089 Cr |
| 22 | GlaxoSmithKline Pharmaceuticals Limited | 101 funds | 0.67% | ₹1,737 Cr |
| 23 | Acutaas Chemicals Ltd | 96 funds | 1.48% | ₹2,848 Cr |
| 24 | Cohance Lifesciences Limited | 93 funds | 0.68% | ₹3,237 Cr |
| 25 | Piramal Pharma Limited | 87 funds | 0.76% | ₹2,873 Cr |
| 26 | Onesource Specialty Pharma Limited | 76 funds | 1.08% | ₹2,387 Cr |
| 27 | Eris Lifesciences Limited | 74 funds | 0.77% | ₹3,363 Cr |
| 28 | Wockhardt Limited | 73 funds | 0.83% | ₹1,847 Cr |
| 29 | Pfizer Limited | 73 funds | 0.71% | ₹2,409 Cr |
| 30 | Emcure Pharmaceuticals Limited | 62 funds | 0.60% | ₹1,572 Cr |
| 31 | Natco Pharma Limited | 60 funds | 0.67% | ₹319 Cr |
| 32 | Jubilant Pharmova Limited | 55 funds | 0.66% | ₹993 Cr |
| 33 | Concord Biotech Limited | 48 funds | 0.35% | ₹454 Cr |
| 34 | Granules India Limited | 45 funds | 0.48% | ₹310 Cr |
| 35 | Caplin Point Laboratories Limited | 42 funds | 0.27% | ₹240 Cr |
| 36 | Blue Jet Healthcare Ltd | 39 funds | 0.11% | ₹129 Cr |
| 37 | AstraZeneca Pharma India Limited | 37 funds | 0.83% | ₹1,148 Cr |
| 38 | SANOFI CONSUMER HEALTHCARE | 36 funds | 0.79% | ₹1,486 Cr |
| 39 | Alembic Pharmaceuticals Limited | 29 funds | 0.65% | ₹1,195 Cr |
| 40 | Corona Remedies Limited | 26 funds | 0.91% | ₹654 Cr |
The table above ranks the top 20 stocks in the Pharmaceuticals & Biotechnology sector by the number of Indian mutual fund schemes holding them as of April 2026. When a large number of fund managers independently choose the same stock, it is a powerful signal of institutional conviction — these are the stocks that professional money managers believe in most.
A stock held by 200+ mutual funds means that hundreds of fund managers — each doing their own independent research — have concluded that this stock deserves a place in their portfolio. This collective wisdom is one of the most reliable indicators of a stock's quality within its sector. The average weight shows how much of their portfolio each fund typically allocates to the stock, and the total MF value shows the combined rupee investment across all funds holding it.
All data is sourced from monthly portfolio disclosures that every AMFI-registered mutual fund is required to publish. RightAdvise compiles and analyses this data across 1,100+ active fund schemes to give you a clear, unbiased view of where professional fund managers are investing in the Pharmaceuticals & Biotechnology sector. Click any stock name in the table to see which specific funds hold it and in what proportion.